author-photo

Roman Kischel

Amgen

80

Papers

1391

Citations

Citation Trend

Filter By

Papers (51) Sort By

Journal Conference Others

Treatment-Free Intervals during CD19xCD3 BiTE ® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
P-76 A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
REDIRECTED CYTOTOXICITY AND PROLIFERATION OF T CELLS INDUCED BY BITE® ANTIBODY CONSTRUCTS ARE MODULATED BY THE EXPRESSION PROFILE OF COSTIMULATORY AND COINHIBITORY MOLECULES ON TARGET CELLS IN VITRO: PF231

2019
Show All
- Source
- Cite
- Save
Citations (0)
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

2019 OncoImmunology
Show All
- Source
- Cite
- Save
Citations (26)
Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

2019 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option

2018 Oncogene
Show All
- Source
- Cite
- Save
Citations (37)
Generation of a Half-Life Extended Anti-CD19 BiTE® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of CD19-Positive Malignancies

2017 Blood
Show All
- Source
- Cite
- Save
Citations (20)
Administration d'une construction bispécifique se liant à cd33 et cd3 destinée à une utilisation dans un procédé de traitement de la leucémie myéloïde

2017
Show All
- Source
- Cite
- Save
Citations (0)
CD33/CD3-Bispecific T-Cell Engaging (BiTE®) Antibody Constructs Efficiently Target Monocytic CD14+ hla-DRlow IDO+ aml-MDSCs

2017 Blood
Show All
- Source
- Cite
- Save
Citations (2)